Metrics as of 10/16/2026, 08:44 AM (Berlin time), refresh in progress.
Genus Stock
Genus plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Jorgen Kokke
- Employees
- 3,054
- Market cap
- £1.5 B
- IPO
- 06/07/2000
Genus plc is a global animal genetics company operating within the Healthcare sector and the Biotechnology industry. Headquartered in Basingstoke, United Kingdom, the company was established in 1994. With 3,054 employees, its business operations are divided into three key segments: Genus PIC, Genus ABS, and Genus…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Genus stock: price history
1D
-1.9%
1W
+1.6%
1M
+7.7%
6M
-12.4%
YTD
-10.8%
1Y
-13.9%
2Y
+11.6%
5Y
-57.3%
10Y
+16.4%
Next earnings date
Next earnings date
25/02/2027 (in 131 days)
Volatility around earnings
~76% stronger price swings than usual
Ask the agents about Genus
Genus stock metrics
P/E
5.37
P/B
2.01
EV/EBITDA
12.34
RETURN ON EQUITY
33.3%
NET MARGIN
79.2%
DEBT/EQUITY
0.14
DIVIDEND YIELD
1.4%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.6%
FLOAT SHARES
62,011,078
AVG. DAILY VOLUME (30D)
247,410
Dividends
Comparable stocks
Frequently asked questions about Genus stock
What does Genus do?
Genus plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Jorgen Kokke, the company employs around 3,054 people.
The IPO was on 06/07/2000; the stock trades on LSE under the ticker GNS.L.
When does Genus report next?
The next earnings date is 25/02/2027.
Around past earnings, price swings were roughly 76% stronger than usual.
Does Genus pay a dividend?
Yes. The last dividend was £24.00 per share, ex-date 12/11/2026, paid on 04/12/2026.
The dividend yield is 1.4% (as of 30/06/2026).
Which stocks are comparable to Genus?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Genus stock analyzed?
Clicking "Analyze stock" lets five strategies assess Genus against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.